Auriga reiterates a 'Buy' on inVentiv Health (Nasdaq: VTIV). Price target increased from $14 to $17.

Auriga analyst says, "Earnings ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE